Oculis (NASDAQ:OCS) Price Target Cut to $40.00 by Analysts at Guggenheim

Oculis (NASDAQ:OCS) had its price target lowered by Guggenheim to $40.00 in a research note published on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

OCS has been the topic of a number of other reports. JPMorgan Chase & Co. decreased their price objective on Oculis from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Friday, August 14th. HC Wainwright reissued a “buy” rating and issued a $39.00 target price on shares of Oculis in a report on Wednesday, October 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research report on Thursday, October 15th. Finally, Wall Street Zen upgraded Oculis from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Oculis presently has a consensus rating of “Moderate Buy” and an average target price of $38.89.

Oculis Price Performance

Shares of Oculis stock opened at $7.28 on Wednesday. The firm has a market cap of $422.09 million, a P/E ratio of -4.26 and a beta of 0.67. The firm’s 50-day simple moving average is $9.42 and its 200-day simple moving average is $18.54. Oculis has a twelve month low of $6.80 and a twelve month high of $34.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.35 and a current ratio of 8.35.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.10. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.26 million. Oculis had a negative net margin of 8,613.92% and a negative return on equity of 39.31%. As a group, research analysts expect that Oculis will post -2.01 EPS for the current fiscal year.

Institutional Trading of Oculis

Several large investors have recently added to or reduced their stakes in the company. Alps Advisors Inc. increased its holdings in shares of Oculis by 40.7% during the third quarter. Alps Advisors Inc. now owns 81,619 shares of the company’s stock worth $762,000 after buying an additional 23,600 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Oculis in the 3rd quarter worth approximately $74,000. Squarepoint Ops LLC boosted its holdings in shares of Oculis by 326.4% in the 2nd quarter. Squarepoint Ops LLC now owns 61,605 shares of the company’s stock worth $854,000 after acquiring an additional 47,158 shares in the last quarter. Braidwell LP acquired a new position in shares of Oculis in the 2nd quarter worth approximately $11,570,000. Finally, Bank of America Corp DE grew its position in Oculis by 9.1% during the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock worth $1,855,000 after acquiring an additional 5,813 shares during the last quarter. 22.30% of the stock is owned by institutional investors.

Oculis Company Profile

Oculis is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company’s research is centered on therapies that can be administered directly to the eye, including topical ophthalmic formulations and other approaches designed to improve drug delivery, efficacy, and patient convenience.

Oculis has developed a pipeline addressing ophthalmic conditions such as retinal diseases, diabetic macular edema, dry eye disease, and other disorders that can impair vision.